{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T20:28:11Z","timestamp":1776976091505,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00417-025-07087-y","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:46:44Z","timestamp":1767768404000},"page":"1089-1100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic immunosuppressive therapy in idiopathic non-infectious uveitis and scleritis: disease remission, discontinuation, and relapse patterns"],"prefix":"10.1007","volume":"264","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3592-2820","authenticated-orcid":false,"given":"Ana Margarida","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"Marta In\u00eas","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Ana Catarina","family":"Pedrosa","sequence":"additional","affiliation":[]},{"given":"Cl\u00e1udia Oliveira","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"S\u00f3nia","family":"Torres-Costa","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Figueira","sequence":"additional","affiliation":[]},{"given":"Joana Rodrigues","family":"Ara\u00fajo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"issue":"5","key":"7087_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.reumae.2017.09.004","volume":"15","author":"C Mill\u00e1n-Longo","year":"2019","unstructured":"Mill\u00e1n-Longo C, Peiteado D, Schlincker A, Hidalgo V, Pieren A, Balsa A et al (2019) Use of immunomodulatory drugs at a uveitis clinic. Reumatolog\u00eda Cl\u00ednica (English Edition) 15(5):271\u2013276","journal-title":"Reumatolog\u00eda Cl\u00ednica (English Edition)"},{"issue":"5","key":"7087_CR2","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/09273948.2023.2201324","volume":"32","author":"JQ Li","year":"2024","unstructured":"Li JQ, Welchowski T, Schmid M, Finger RP (2024) Prevalence and incidence of registered severe visual impairment and blindness due to uveitis in Germany. Ocul Immunol Inflamm 32(5):735\u2013739","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"7087_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3414\/ME12-01-0063","volume":"52","author":"B Trusko","year":"2013","unstructured":"Trusko B, Thorne J, Jabs D, Belfort R, Dick A, Gangaputra S et al (2013) The standardization of uveitis nomenclature (SUN) Project. Development of a clinical evidence base utilizing informatics tools and techniques. Methods Inf Med 52(3):259\u2013265 s1-6","journal-title":"Methods Inf Med"},{"issue":"4","key":"7087_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","volume":"130","author":"DA Jabs","year":"2000","unstructured":"Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS et al (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130(4):492\u2013513","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"7087_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/17469899.2017.1319762","volume":"12","author":"JE Knickelbein","year":"2017","unstructured":"Knickelbein JE, Kim M, Argon E, Nussenblatt RB, Sen NH (2017) Comparative efficacy of steroid-sparing therapies for non-infectious uveitis. Expert Rev Ophthalmol 12(4):313\u2013319","journal-title":"Expert Rev Ophthalmol"},{"key":"7087_CR6","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-G\u00f3mez A, Loza E, Rosario MP, Espinosa G, de Morales JMGR, Herrera JM et al (eds) (2020) Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: a systematic literature review. Seminars in Arthritis and Rheumatism:Elsevier","DOI":"10.1016\/j.semarthrit.2020.08.010"},{"issue":"4","key":"7087_CR7","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1136\/bjo-2024-326239","volume":"109","author":"JA Branford","year":"2025","unstructured":"Branford JA, Bodaghi B, Ferreira LB, McCluskey PJ, Thorne JE, Matthews JM et al (2025) Use of immunomodulatory treatment for non-infectious uveitis: an international ocular inflammation society report of real-world practice. Br J Ophthalmol 109(4):482\u2013489","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"7087_CR8","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","volume":"125","author":"AD Dick","year":"2018","unstructured":"Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R Jr., Br\u00e9zin AP, Chee SP et al (2018) Guidance on noncorticosteroid systemic Immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (FOCUS) initiative. Ophthalmology 125(5):757\u2013773","journal-title":"Ophthalmology"},{"issue":"11","key":"7087_CR9","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","volume":"116","author":"S Gangaputra","year":"2009","unstructured":"Gangaputra S, Newcomb CW, Liesegang TL, Ka\u00e7maz RO, Jabs DA, Levy-Clarke GA et al (2009) Methotrexate for ocular inflammatory diseases. Ophthalmology 116(11):2188\u201398e1","journal-title":"Ophthalmology"},{"issue":"6","key":"7087_CR10","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0161-6420(01)00576-0","volume":"108","author":"CM Samson","year":"2001","unstructured":"Samson CM, Waheed N, Baltatzis S, Foster CS (2001) Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 108(6):1134\u20131139","journal-title":"Ophthalmology"},{"issue":"1","key":"7087_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3341\/kjo.2012.26.1.21","volume":"26","author":"SH Lee","year":"2012","unstructured":"Lee SH, Chung H, Yu HG (2012) Clinical outcomes of cyclosporine treatment for noninfectious uveitis. Korean J Ophthalmol 26(1):21\u201325","journal-title":"Korean J Ophthalmol"},{"issue":"4","key":"7087_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1089\/jop.2016.0155","volume":"33","author":"WM Smith","year":"2017","unstructured":"Smith WM (2017) Cyclosporine: a historical perspective on its role in the treatment of noninfectious uveitis. J Ocul Pharmacol Ther 33(4):247\u2013262","journal-title":"J Ocul Pharmacol Ther"},{"issue":"7","key":"7087_CR13","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/09273948.2017.1411518","volume":"26","author":"F Mackensen","year":"2018","unstructured":"Mackensen F, Heinz C, Jakob E, Grewing V, Lorenz HM, Heiligenhaus A et al (2018) Randomized controlled study to evaluate the efficacy of adalimumab in patients with different forms of refractory uveitis. Ocul Immunol Inflamm 26(7):1015\u201322","journal-title":"Ocul Immunol Inflamm"},{"key":"7087_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14534","author":"C Gaggiano","year":"2025","unstructured":"Gaggiano C, de-la\u2010Torre A, Guerriero S, Costi S, Ragab G, Paroli MP et al (2025) Adalimumab monotherapy or combination therapy with methotrexate in paediatric uveitis: data from the AIDA network uveitis registry. Clin Exp Ophthalmol. https:\/\/doi.org\/10.1111\/ceo.14534","journal-title":"Clin Exp Ophthalmol"},{"issue":"3","key":"7087_CR15","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","volume":"117","author":"RO Ka\u00e7maz","year":"2010","unstructured":"Ka\u00e7maz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB et al (2010) Cyclosporine for ocular inflammatory diseases. Ophthalmology 117(3):576\u2013584","journal-title":"Ophthalmology"},{"issue":"6","key":"7087_CR16","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.ophtha.2020.10.036","volume":"128","author":"EB Suhler","year":"2021","unstructured":"Suhler EB, Jaffe GJ, Fortin E, Lim LL, Merrill PT, Dick AD et al (2021) Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology 128(6):899\u2013909","journal-title":"Ophthalmology"},{"key":"7087_CR17","doi-asserted-by":"crossref","unstructured":"Pasadhika S, Rosenbaum JT (2014) Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biol Targets Ther 8:67\u201381","DOI":"10.2147\/BTT.S41477"},{"issue":"7","key":"7087_CR18","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","volume":"125","author":"EB Suhler","year":"2018","unstructured":"Suhler EB, Ad\u00e1n A, Br\u00e9zin AP, Fortin E, Goto H, Jaffe GJ et al (2018) Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology 125(7):1075\u20131087","journal-title":"Ophthalmology"},{"issue":"3","key":"7087_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/1744666X.2017.1288097","volume":"13","author":"KC LaMattina","year":"2017","unstructured":"LaMattina KC, Goldstein DA (2017) Adalimumab for the treatment of uveitis. Expert Rev Clin Immunol 13(3):181\u2013188","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"7087_CR20","first-page":"158","volume":"93","author":"I Mili-Boussen","year":"2015","unstructured":"Mili-Boussen I, Zitouni M, Ammous I, Letaief I, Errais K, Zhioua R et al (2015) Azathioprine for glucocorticoid resistant noninfectious uveitis. Tunis Med 93(3):158\u2013163","journal-title":"Tunis Med"},{"key":"7087_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ajo.2019.03.024","volume":"223","author":"JH Kempen","year":"2021","unstructured":"Kempen JH, Pistilli M, Begum H, Fitzgerald TD, Liesegang TL, Payal A et al (2021) Remission of non-infectious anterior scleritis: incidence and predictive factors. Am J Ophthalmol 223:377\u201395","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"7087_CR22","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ophtha.2013.09.041","volume":"121","author":"P Artornsombudh","year":"2014","unstructured":"Artornsombudh P, Pistilli M, Foster CS, Pujari SS, Gangaputra SS, Jabs DA et al (2014) Factors predictive of remission of new-onset anterior uveitis. Ophthalmology 121(3):778\u2013784","journal-title":"Ophthalmology"},{"key":"7087_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2024.2311743","author":"M Azzopardi","year":"2024","unstructured":"Azzopardi M, Chong YJ, Sreekantam S, Barry RJ, Poonit N, Rauz S et al (2025) Real-world experience in the use of immunosuppression for the management of inflammatory eye disease. Ocul Immunol Inflamm 33(7):1119\u20131128. https:\/\/doi.org\/10.1080\/09273948.2024.2311743","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"7087_CR24","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/j.jaapos.2017.07.122","volume":"21","author":"US Saboo","year":"2017","unstructured":"Saboo US, Abraham A, Ronconi C, Ducca BL, Lawand AT, Cao JH (2017) Time to steroid-free remission of uveitis in pediatric population. J Am Assoc Pediatr Ophthalmol Strabismus 21(4):e35","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus"},{"issue":"7","key":"7087_CR25","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/archopht.123.7.903","volume":"123","author":"EB Suhler","year":"2005","unstructured":"Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD et al (2005) A prospective trial of Infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123(7):903\u2013912","journal-title":"Arch Ophthalmol"},{"key":"7087_CR26","doi-asserted-by":"crossref","unstructured":"Niccoli L, Nannini C, Benucci M, Chindamo D, Cassar\u00e0 E, Salvarani C et al (2007) Long-term efficacy of infliximab in refractory posterior uveitis of Behcet\u2019s disease: a 24-month follow-up study. Rheumatology (Oxford) 46(7):1161\u20131164","DOI":"10.1093\/rheumatology\/kem101"},{"issue":"2","key":"7087_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10792-013-9788-5","volume":"34","author":"M Mesquida","year":"2014","unstructured":"Mesquida M, Molins B, Lloren\u00e7 V, Hern\u00e1ndez MV, Espinosa G, Dick AD et al (2014) Current and future treatments for Beh\u00e7et\u2019s uveitis: road to remission. Int Ophthalmol 34(2):365\u2013381","journal-title":"Int Ophthalmol"},{"key":"7087_CR28","first-page":"1","volume":"Suppl","author":"QD Nguyen","year":"2006","unstructured":"Nguyen QD, Callanan D, Dugel P, Godfrey DG, Goldstein DA, Wilensky JT (2006) Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion. Retina Suppl:1\u201316","journal-title":"Proceedings of an expert panel roundtable discussion. Retina"},{"issue":"11","key":"7087_CR29","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3928\/23258160-20240625-01","volume":"55","author":"RP Singh","year":"2024","unstructured":"Singh RP, Albini TA, Baumal CR, Chang PY, Eichenbaum D, Holekamp N et al (2024) Development of a consensus guideline for the diagnosis and management of chronic noninfectious uveitis affecting the posterior segment. Ophthalmic Surg Lasers Imaging Retina 55(11):652\u20138","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"6","key":"7087_CR30","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.ophtha.2019.11.020","volume":"127","author":"L Sobrin","year":"2020","unstructured":"Sobrin L, Pistilli M, Dreger K, Kothari S, Khachatryan N, Artornsombudh P et al (2020) Factors predictive of remission of chronic anterior uveitis. Ophthalmology 127(6):826\u2013834","journal-title":"Ophthalmology"},{"key":"7087_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ajo.2015.12.034","volume":"164","author":"JH Kempen","year":"2016","unstructured":"Kempen JH, Gewaily DY, Newcomb CW, Liesegang TL, Ka\u00e7maz RO, Levy-Clarke GA et al (2016) Remission of intermediate uveitis: incidence and predictive factors. Am J Ophthalmol 164:110\u20137e2","journal-title":"Am J Ophthalmol"},{"key":"7087_CR32","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/310329","volume":"2014","author":"JR Maya","year":"2014","unstructured":"Maya JR, Sadiq MA, Zapata LJ, Hanout M, Sarwar S, Rajagopalan N et al (2014) Emerging therapies for noninfectious uveitis: what may be coming to the clinics. J Ophthalmol 2014:310329","journal-title":"J Ophthalmol"},{"issue":"0910","key":"7087_CR33","doi-asserted-by":"publisher","first-page":"w20025","DOI":"10.4414\/smw.2019.20025","volume":"149","author":"DC Rossi","year":"2019","unstructured":"Rossi DC, Ribi C, Guex-Crosier Y (2019) Treatment of chronic non-infectious uveitis and scleritis. Swiss Med Wkly 149(0910):w20025\u2013w","journal-title":"Swiss Med Wkly"},{"issue":"2","key":"7087_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2017.08.007","volume":"125","author":"DA Jabs","year":"2018","unstructured":"Jabs DA (2018) Immunosuppression for the uveitides. Ophthalmology 125(2):193\u2013202","journal-title":"Ophthalmology"},{"issue":"12","key":"7087_CR35","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1002\/art.40235","volume":"69","author":"PP Sfikakis","year":"2017","unstructured":"Sfikakis PP, Arida A, Panopoulos S, Fragiadaki K, Pentazos G, Laskari K et al (2017) Brief report: drug-free long-term remission in severe Beh\u00e7et\u2019s disease following withdrawal of successful anti-tumor necrosis factor treatment. Arthritis Rheum 69(12):2380\u20135","journal-title":"Arthritis Rheum"},{"issue":"2","key":"7087_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.5301\/ejo.5001050","volume":"28","author":"C You","year":"2018","unstructured":"You C, Ma L, Anesi SD, Stephen Foster C (2018) Long-term remission of ocular cicatricial pemphigoid off immunomodulatory therapy. Eur J Ophthalmol 28(2):157\u2013162","journal-title":"Eur J Ophthalmol"},{"issue":"10475","key":"7087_CR37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(24)02468-1","volume":"405","author":"NR Acharya","year":"2025","unstructured":"Acharya NR, Ramanan AV, Coyne AB, Dudum KL, Rubio EM, Woods SM et al (2025) Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial. Lancet 405(10475):303\u201313","journal-title":"Lancet"},{"issue":"6","key":"7087_CR38","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/acr.23871","volume":"71","author":"ST Angeles-Han","year":"2019","unstructured":"Angeles-Han ST, Ringold S, Beukelman T, Lovell D, Cuello CA, Becker ML et al (2019) 2019 American College of Rheumatology\/Arthritis Foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res (Hoboken) 71(6):703\u201316","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"7087_CR39","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1136\/annrheumdis-2018-213131","volume":"77","author":"T Constantin","year":"2018","unstructured":"Constantin T, Foeldvari I, Anton J, de Boer J, Czitrom-Guillaume S, Edelsten C et al (2018) Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis 77(8):1107\u201317","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"7087_CR40","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.3390\/jcm10132934","volume":"10","author":"P Quartier","year":"2021","unstructured":"Quartier P (2021) Juvenile idiopathic arthritis-associated chronic uveitis: recent therapeutic approaches. J Clin Med 10(13):2934","journal-title":"J Clin Med"},{"issue":"6","key":"7087_CR41","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.ophtha.2019.11.024","volume":"127","author":"V Lloren\u00e7","year":"2020","unstructured":"Lloren\u00e7 V, Cordero-Coma M, Blanco-Esteban A, Heras-Mulero H, Losada-Castillo M-J, Jovani-Casano V et al (2020) Drug retention rate and causes of discontinuation of adalimumab in uveitis. Ophthalmology 127(6):814\u201325","journal-title":"Ophthalmology"},{"key":"7087_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2016.06.007","volume":"169","author":"L Ab\u00e1solo","year":"2016","unstructured":"Ab\u00e1solo L, Rosales Z, D\u00edaz-Valle D, G\u00f3mez-G\u00f3mez A, Pe\u00f1a-Blanco RC, Prieto-Garc\u00eda \u00c1 et al (2016) Immunosuppressive drug discontinuation in noninfectious uveitis from real-life clinical practice: a survival analysis. Am J Ophthalmol 169:1\u20138","journal-title":"Am J Ophthalmol"},{"key":"7087_CR43","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2147\/OPTH.S180580","volume":"13","author":"H Massa","year":"2019","unstructured":"Massa H, Pipis SY, Adewoyin T, Vergados A, Patra S, Panos GD (2019) Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. Clin Ophthalmol 13:1761\u20131777","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"7087_CR44","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ophtha.2013.09.023","volume":"121","author":"MH Levin","year":"2014","unstructured":"Levin MH, Pistilli M, Daniel E, Gangaputra SS, Nussenblatt RB, Rosenbaum JT et al (2014) Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology 121(2):588\u2013595 e1","journal-title":"Ophthalmology"},{"issue":"10","key":"7087_CR45","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/j.ophtha.2014.04.044","volume":"121","author":"EB Suhler","year":"2014","unstructured":"Suhler EB, Lim LL, Beardsley RM, Giles TR, Pasadhika S, Lee ST et al (2014) Rituximab therapy for refractory scleritis. Ophthalmology 121(10):1885\u201391","journal-title":"Ophthalmology"},{"issue":"2","key":"7087_CR46","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/APO.0000000000000341","volume":"10","author":"PD Majumder","year":"2021","unstructured":"Majumder PD, Agrawal R, McCluskey P, Biswas J (2021) Current approach for the diagnosis and management of noninfective scleritis. Asia-Pac J Ophthalmol 10(2):212\u2013223","journal-title":"Asia-Pac J Ophthalmol"},{"issue":"8","key":"7087_CR47","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1586\/1744666X.2016.1171713","volume":"12","author":"M Oray","year":"2016","unstructured":"Oray M, Meese H, Foster CS (2016) Diagnosis and management of non-infectious immune-mediated scleritis: current status and future prospects. Expert Rev Clin Immunol 12(8):827\u2013837","journal-title":"Expert Rev Clin Immunol"},{"issue":"2\u20133","key":"7087_CR48","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000485262","volume":"239","author":"L Borrego-Sanz","year":"2018","unstructured":"Borrego-Sanz L, Ab\u00e1solo L, L\u00f3pez-Abad C, Fern\u00e1ndez-Guti\u00e9rrez B, Garc\u00eda-Feijoo J, Diaz-Valle D et al (2018) Disease remission in children and adolescents with intermediate uveitis: a survival analysis. Ophthalmologica 239(2\u20133):151\u2013158","journal-title":"Ophthalmologica"},{"issue":"10","key":"7087_CR49","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.ophtha.2011.02.044","volume":"118","author":"L Grunwald","year":"2011","unstructured":"Grunwald L, Newcomb CW, Daniel E, Ka\u00e7maz RO, Jabs DA, Levy-Clarke GA et al (2011) Risk of relapse in primary acute anterior uveitis. Ophthalmology 118(10):1911\u20131915","journal-title":"Ophthalmology"},{"issue":"5","key":"7087_CR50","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/bjophthalmol-2020-316776","volume":"105","author":"R Agrawal","year":"2021","unstructured":"Agrawal R, Testi I, Lee CS, Tsui E, Blazes M, Thorne JE et al (2021) Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic. Br J Ophthalmol 105(5):639\u2013647","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"7087_CR51","first-page":"220","volume":"155","author":"G Espinosa","year":"2020","unstructured":"Espinosa G, Herreras JM, Mu\u00f1oz-Fern\u00e1ndez S, de Morales JMGR, Cordero-Coma M (2020) Recommendations statement on the immunosuppressive treatment of non-infectious, non-neoplastic, non-anterior uveitis. Med Cl\u00ednica (English Edition) 155(5):220 e1-. e12","journal-title":"Med Cl\u00ednica (English Edition)"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07087-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-07087-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07087-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:02:36Z","timestamp":1773914556000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-07087-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7087"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-07087-y","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the (place name of institution and\/or national research committee) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study. Institute (IRB) that approved the study: The study was approved by the Institutional Ethics Review Board of Local Health Unit of S\u00e3o Jo\u00e3o, Porto, Portugal (CES - Comiss\u00e3o de \u00c9tica para a Sa\u00fade). This article was redacted according to the recommendations of The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}